Vera Therapeutics, Inc. (VERA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
VERA currently has 71.5M outstanding shares. with moderate dilution risk from 35.4M authorized shares representing 49.6% potential dilution. The company has significantly diluted shareholders by 28.6% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 71.5M shares outstanding |
71M | 35M |
| Nov 05, 2025 |
10-Q filing | 63.8M shares outstanding |
64M | 35M |
| Aug 05, 2025 |
10-Q filing | 63.8M shares outstanding |
64M | 35M |
| May 07, 2025 |
10-Q filing | 63.7M shares outstanding |
64M | 35M |
| Feb 28, 2025 |
10-K filing | 63.7M shares outstanding |
64M | 35M |
| Nov 07, 2024 |
10-Q filing | 63.3M shares outstanding |
63M | 35M |
| Aug 08, 2024 |
10-Q filing | 54.7M shares outstanding |
55M | 35M |
| May 10, 2024 |
10-Q filing | 51.0M shares outstanding |
51M | 35M |
| Mar 27, 2024 |
10-K filing | 54.5M shares outstanding |
54M | 35M |
| Nov 09, 2023 |
10-Q filing | 44.4M shares outstanding |
44M | 35M |
| Aug 10, 2023 |
10-Q filing | 44.3M shares outstanding |
44M | 35M |
| May 11, 2023 |
10-Q filing | 44.3M shares outstanding |
44M | 35M |
| Mar 28, 2023 |
10-K filing | 44.3M shares outstanding |
44M | 35M |
| Nov 09, 2022 |
10-Q filing | 27.2M shares outstanding |
27M | 35M |
| Aug 10, 2022 |
10-Q filing | 27.1M shares outstanding |
27M | 35M |
| Jun 03, 2022 |
S-3 filing: The company may offer up to $400,000,000 of any combination of Class A common stock, preferred stock, debt securities and warrants from time to time in one or more offerings. |
27M | 35M |
| May 16, 2022 |
10-Q filing | 26.8M shares outstanding |
27M | 7.3M |
| Mar 28, 2022 |
10-K filing | 26.7M shares outstanding |
27M | 7.3M |
| Feb 07, 2022 |
S-1 filing: This S-1 filing indicates an offering of 4,000,000 shares of Class A common stock, with an additional 600,000 shares available to underwriters, and provides information on outstanding shares, use of proceeds, voting rights, and risk factors. |
21M | 7.3M |
| Nov 10, 2021 |
10-Q filing | 21.0M shares outstanding |
21M | 2.7M |
| Aug 16, 2021 |
10-Q filing | 21.0M shares outstanding |
21M | 2.7M |
| Jun 24, 2021 |
10-Q filing | 0.4M shares outstanding |
360K | 2.7M |
| May 12, 2021 |
S-1/A filing: This is an S-1/A filing with information regarding unregistered securities issued by the company since January 1, 2018, including options and shares of Class A common stock, as well as convertible promissory notes and Series C preferred stock. |
N/A | 2.7M |
| May 10, 2021 |
S-1/A filing: This is an S-1/A filing for an initial public offering. The filing includes information regarding previous issuances of common stock, preferred stock, and convertible notes. |
N/A | 2.7M |
| Apr 23, 2021 |
S-1 filing: This is an S-1 filing that includes information regarding voting rights, conversion rights, recent sales of unregistered securities, including options and shares of Class A common stock, and convertible promissory notes. |
N/A | 31M |